약물유전체학 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Pharmacogenomics Market was valued at USD 5.7 billion in 2025 and is estimated to grow at a CAGR of 10.6% to reach USD 15.4 billion by 2035.

The global pharmacogenomics market is witnessing momentum as healthcare systems increasingly integrate genetic insights into clinical decision-making processes. Market growth is supported by the rising adoption of precision diagnostics, expanding availability of multi-gene testing technologies, and increasing use of bioinformatics platforms that enable personalized treatment strategies. Regulatory advancements, declining sequencing costs, and growing awareness of the benefits associated with genetics-based prescribing continue to accelerate market adoption. Healthcare organizations are increasingly recognizing the value of pharmacogenomics in improving treatment outcomes, reducing medication-related risks, and optimizing healthcare resource utilization. Expanding clinical applications across multiple therapeutic areas, combined with growing investments in genomic infrastructure, continue to create significant opportunities for market participants. Pharmaceutical companies, research institutions, and healthcare providers are increasingly incorporating genetic information into drug development and patient management processes. These developments, along with continuous technological innovation and broader clinical accessibility, are expected to support the sustained growth of the global pharmacogenomics market throughout the forecast period.

The products segment held 67% share in 2025 and is projected to grow at a CAGR of 10.5% through 2035. The segment includes a wide range of technologies and solutions, such as next-generation sequencing systems, PCR-based testing products, microarray technologies, sample preparation tools, bioinformatics platforms, companion diagnostic solutions, and laboratory automation equipment. Increasing demand for advanced genetic analysis capabilities and expanding adoption of precision medicine workflows continue to drive strong growth within the product segment.

The hospitals and clinics segment held 37.9% share in 2025, growing at a CAGR of 10.4% through 2035. This segment includes healthcare institutions, specialty care facilities, and physician practices that increasingly utilize pharmacogenomic testing to support personalized treatment decisions. Growing integration of genetic testing into routine healthcare processes, increasing clinical awareness, and expanding demand for optimized drug selection continue to strengthen adoption among healthcare providers. The rising focus on improving treatment effectiveness and minimizing medication-related complications further supports the expansion of pharmacogenomics applications across hospitals and clinical environments.

North America Pharmacogenomics Market accounted for 48.4% share in 2025 and is forecast to grow at a CAGR of 10.4% through 2035. The region maintains its leadership position due to strong healthcare infrastructure, advanced genomic research capabilities, supportive regulatory frameworks, and increasing adoption of precision medicine practices. The United States represents the primary contributor to regional growth, supported by expanding clinical implementation of pharmacogenomic testing, increasing investments in genomic technologies, and growing integration of genetic information into healthcare decision-making processes. Continued development of precision healthcare systems is expected to reinforce North America's dominant position in the global market.

Major companies operating in the global pharmacogenomics market include Illumina, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen, Danaher Corporation, Agilent Technologies, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Charles River Laboratories, Eurofins Scientific, LabCorp, Revvity, Novogene Co., Ltd., Takara Bio Inc., Genomind, OneOme, Genelex, and Admera Health. Companies operating in the global pharmacogenomics market focus on technological innovation, strategic partnerships, and the expansion of precision medicine solutions to strengthen their market position. Leading organizations continue investing in research and development to improve genetic testing accuracy, sequencing capabilities, data analysis platforms, and clinical integration solutions. Many companies expand their offerings through advanced diagnostic products, customized testing services, and bioinformatics technologies designed to support personalized healthcare applications. Strategic collaborations with pharmaceutical companies, healthcare providers, and research institutions help accelerate innovation and broaden market adoption. Businesses also emphasize regulatory compliance, scalable testing infrastructure, and digital healthcare integration to enhance their competitive advantage.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Offering trends
  • 2.1.3 Technology trends
  • 2.1.4 Application trends
  • 2.1.5 Disease area trends
  • 2.1.6 End use trends
  • 2.1.7 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for precision medicine
    • 3.2.1.2 Rising burden of adverse drug reactions
    • 3.2.1.3 Advancements in genomic technologies
    • 3.2.1.4 Increasing prevalence of chronic diseases
    • 3.2.1.5 Increasing adoption of pharmacogenomics in drug development and clinical workflows
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Cost and reimbursement challenges
    • 3.2.2.2 Complexity and interpretation of genetic data
  • 3.2.3 Market opportunities
    • 3.2.3.1 Innovation in microbiome-based and hormone-targeted therapies
    • 3.2.3.2 Development of multi-gene panels and companion diagnostics
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Regulatory landscape (Driven by primary research)
  • 3.5.1 North America
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
  • 3.5.4 Latin America
  • 3.5.5 MEA
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends
• 3.9 Impact of AI and Generative AI on the market (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Offering, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Kits and reagents
  • 5.2.2 Instruments
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Sequencing
• 6.3 PCR
• 6.4 Microarray
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Personalized medicine
• 7.3 Clinical research
• 7.4 Drug discovery and preclinical development
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Disease Area, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Cardiovascular diseases
• 8.4 Neurological diseases
• 8.5 Infectious diseases
• 8.6 Mental health
• 8.7 Other disease areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Academic and research institutions
• 9.4 Pharmaceutical and biotechnology companies
• 9.5 Contract research organizations (CROs)
• 9.6 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Admera Health
• 11.2 Agilent Technologies Inc.
• 11.3 Becton, Dickinson and Company
• 11.4 Bio-Rad Laboratories Inc.
• 11.5 Charles River Laboratories
• 11.6 Danaher Corporation
• 11.7 Eurofins Scientific
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Genelex
• 11.10 Genomind
• 11.11 Illumina Inc.
• 11.12 Labcorp Holdings Inc.
• 11.13 Novogene Co., Ltd.
• 11.14 OneOme
• 11.15 Qiagen N.V.
• 11.16 Revvity
• 11.17 Takara Bio Inc.
• 11.18 Thermo Fisher Scientific Inc.